Supernus Pharmaceuticals Quarterly Income Statement
NASDAQ: SUPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Supernus Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Supernus Pharmaceuticals generated $219.1 million in revenue, up 32.4% from the same quarter a year earlier. Supernus Pharmaceuticals reported a net loss of $58.4 million, compared with net income of $22.5 million a year earlier. Gross margin was 84.6% (down from 89.8%) and operating margin -26.5%.
Diluted earnings per share came in at -$1.01, down from $0.40.
Summary generated from market data by MetaCap's automated system. Methodology
Supernus Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 219.06M | 207.71M | 211.57M | 192.10M | 165.45M | 149.82M | 174.16M | 175.69M | 168.32M | 143.64M | 164.31M | 153.88M |
| Revenue growth (YoY) | +32.40% | +38.63% | +21.48% | +9.34% | -1.71% | +4.30% | +5.99% | +14.17% | +24.17% | -6.58% | -1.80% | -13.24% |
| Cost of Revenue | 33.67M | 23.39M | 23.01M | 18.96M | 16.83M | 15.76M | 26.10M | 17.58M | 17.92M | 16.31M | 19.63M | 19.60M |
| Gross Profit | 185.39M | 184.31M | 188.56M | 173.14M | 148.63M | 134.06M | 148.06M | 158.11M | 150.41M | 127.33M | 144.69M | 134.28M |
| Operating Expenses | 243.35M | 192.65M | 192.50M | 233.37M | 136.49M | 144.32M | 126.66M | 117.26M | 127.84M | 130.49M | 145.68M | 126.14M |
| Research & Development | 29.46M | 39.44M | 27.83M | 29.37M | 22.11M | 26.93M | 28.65M | 29.04M | 26.18M | 24.93M | 23.35M | 22.66M |
| Selling, General & Admin | 133.64M | 125.17M | 122.39M | 179.68M | 93.55M | 89.94M | 79.41M | 69.75M | 85.90M | 86.52M | 81.28M | 82.70M |
| Operating Income | -57.96M | -8.33M | -3.94M | -60.23M | 12.14M | -10.26M | 21.41M | 40.84M | 22.57M | -3.15M | -996.00K | 8.14M |
| Interest Expense | 2.31M | — | — | — | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income (Expense) | 315.00K | 2.38M | 2.02M | 2.28M | 4.53M | 4.42M | 4.98M | 4.10M | 3.73M | 3.40M | 1.99M | 1.75M |
| Pretax Income | -57.65M | -5.95M | -1.91M | -57.95M | 16.67M | -5.83M | 26.38M | 44.94M | 26.30M | 243.00K | 990.00K | 9.89M |
| Income Tax | 723.00K | -3.66M | 2.19M | -12.84M | -5.83M | 6.00M | 11.05M | 6.45M | 6.39M | 119.00K | -185.00K | 25.86M |
| Net Income | -58.37M | -2.29M | -4.11M | -45.12M | 22.50M | -11.83M | 15.33M | 38.50M | 19.92M | 124.00K | 1.18M | -15.98M |
| Net Income growth (YoY) | -359.44% | — | -126.78% | -217.20% | +12.97% | -9637.90% | +1204.51% | — | — | -99.27% | -95.39% | -1013.44% |
| EPS (Basic) | -1.01 | -0.04 | -0.07 | -0.80 | 0.40 | -0.21 | 0.28 | 0.70 | 0.36 | 0.00 | 0.02 | -0.29 |
| EPS (Diluted) | -1.01 | -0.04 | -0.07 | -0.80 | 0.40 | -0.21 | 0.27 | 0.69 | 0.36 | 0.00 | 0.04 | -0.29 |
| Shares Outstanding (Basic) | 58.07M | 57.65M | — | 56.55M | 56.02M | 55.86M | — | 55.15M | 54.98M | 54.80M | — | 54.61M |
| Shares Outstanding (Diluted) | 58.07M | 57.65M | — | 56.55M | 56.64M | 55.86M | — | 56.02M | 55.72M | 55.63M | — | 54.61M |
| EBITDA | -32.22M | 17.80M | 21.08M | -35.42M | 33.50M | 10.13M | 40.25M | 60.95M | 43.29M | 17.60M | 20.68M | 30.00M |
| Gross Margin | 84.63% | 88.74% | 89.13% | 90.13% | 89.83% | 89.48% | 85.01% | 89.99% | 89.36% | 88.65% | 88.06% | 87.26% |
| Operating Margin | -26.46% | -4.01% | -1.86% | -31.35% | 7.34% | -6.85% | 12.29% | 23.25% | 13.41% | -2.20% | -61.00% | 5.29% |
| Net Margin | -26.65% | -110.00% | -1.94% | -23.49% | 13.60% | -7.89% | 8.80% | 21.91% | 11.83% | 9.00% | 72.00% | -10.38% |
This table shows 12 quarterly periods of Supernus Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow SUPN's reporting calendar. What is a income statement?